Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibacterial ribosomal protein inhibitors - Melinta Therapeutics

Drug Profile

Research programme: antibacterial ribosomal protein inhibitors - Melinta Therapeutics

Alternative Names: RX 01413; RX 01423; RX 01445; RX-01; RX-01(a); RX-01(b); RX-01_413; RX-01_423; RX-01_445; RX-02; RX-03; RX-04; RX-04A; RX-04B; RX-04C; RX-04D; RX-05; RX-230; RX-5312; RX-6425; RX-6567; RX-P2177; RX-P2382; RX-P770; RX-P873

Latest Information Update: 30 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rib-X Pharmaceuticals
  • Developer Melinta Therapeutics
  • Class Macrolides; Oxadiazoles; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 23 Apr 2018 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical trials in Bacterial infections presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
  • 19 Mar 2018 Preclinical development is ongoing for Bacterial infections (Melinta Therapeutics Pipeline; 9235557)
  • 13 Mar 2018 Melinta Therapeutics plans IND-enabling studies for lead ESKAPE compound in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top